Ofatumumab in Combination With Glucocorticoids for Primary Therapy of Chronic Graft Versus Host Disease

Trial Profile

Ofatumumab in Combination With Glucocorticoids for Primary Therapy of Chronic Graft Versus Host Disease

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Jun 2018

At a glance

  • Drugs Ofatumumab (Primary) ; Prednisone
  • Indications Graft-versus-host disease
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Jun 2018 Planned End Date changed from 1 Feb 2020 to 1 Jun 2020.
    • 20 Jun 2018 Planned primary completion date changed from 1 Feb 2019 to 1 Jun 2019.
    • 09 Jan 2018 Planned End Date changed from 1 Jun 2019 to 1 Feb 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top